FDA Extends Exubera Review Period by Three Months

Drug Industry Daily
A A

The FDA has extended the review period for Pfizer and sanofi-aventis' potential breakthrough diabetes drug Exubera to review additional technical chemistry data submitted by the sponsors.

To View This Article:

Login

Subscribe To Drug Industry Daily